Abstracts Archive - Page 1184 of 2607 - ACR Meeting Abstracts

Abstract Number: 734 • 2019 ACR/ARP Annual Meeting
Risk Assessment in Connective Tissue Disease Associated Pulmonary Arterial Hypertension
Yuichiro Shirai¹, Hidekata Yasuoka ², Yuichi Tamura ³ and Masataka Kuwana ¹, ¹Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Bunkyo-ku, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Fujita Health University School of Medicine, Aichi, Japan, Toyoake, Aichi, Japan, ³Pulmonary Hypertension Center, International University of Health and Welfare Mita Hospital, Tokyo, Japan, Tokyo, Japan
Background/Purpose: Pulmonary arterial hypertension (PAH) still holds a poor prognosis in patients with connective tissue diseases (CTD), especially those with systemic sclerosis (SSc). A variety…
Abstract Number: 2045 • 2019 ACR/ARP Annual Meeting
RNA Sequencing of Plasma and Urine-derived Extracellular Vesicles from Lupus Nephritis Patients Identifies Disease-associated Small RNA Signatures and Putative Therapeutic Targets
Taylor Koenig¹, Nicholas Young ², Giancarlo Valiente ³, Ifeoma Okafor ⁴, Emily Schwarz ⁵, Peter Harb ⁵, Caitlin Henry ¹, Kyle Jablonski ⁶, Lai-Chu Wu ⁴, Eli Roberson ⁷ and Wael Jarjour ⁸, ¹Division of Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, ²The Ohio State University Wexner Medical Center, Division of Immunology and Rheumatology, Columbus, OH, ³The Ohio State University, Columbus, ⁴Ohio State College of Medicine, Columbus, ⁵The Ohio State University Wexner Medical Center, Columbus, OH, ⁶The Ohio State University Wexner Medical Center, Division of Immunology and Rheumatology, Columbus, ⁷Washington University at St.Louis, St.Louis, MO, ⁸Ohio State College of Medicine, Columbus, OH
Background/Purpose: Systemic lupus erythematosus is an autoimmune disease characterized by chronic inflammation. We have previously shown that TLR7 and TLR8 are significantly upregulated in PBMCs…
Abstract Number: 2703 • 2019 ACR/ARP Annual Meeting
The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA Study: Patient Characteristics, Patient Reported Outcomes and Consensus Treatment Plan Choices
Sarah Ringold ¹, George Tomlinson ², Pamela Weiss ³, Laura Schanberg ⁴, Mary Ellen Riordan ⁵, Anne Dennos ⁶, Vincent Del Gaizo ⁷, Katherine Murphy ⁸, Brian Feldman ⁹ and Yukiko Kimura¹⁰, ¹Seattle Children's, Seattle, ²University of Toronto, Toronto, ON, Canada, ³Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Duke University Medical Center, Durham, NC, ⁵Joseph M Sanzari Children's Hospital at Hackensack University Medical Center, Hackensack, NJ, ⁶Duke Clinical Research Institute, Durham, NC, ⁷Childhood Arthritis & Rheumatology Research Alliance, Whitehouse Station, NJ, ⁸Louisiana Office of Public Health, New Orleans, LA, ⁹University of Toronto & The Hospital for Sick Children, Toronto, ON, Canada, ¹⁰Joseph M Sanzari Children's Hospital, Hackensack University Medical Center, Cincinnati, OH
Background/Purpose: There continues to be uncertainty regarding when to start biologic medications for polyarticular juvenile idiopathic arthritis (P-JIA). The Childhood Arthritis and Rheumatology Research Alliance…
Abstract Number: 2822 • 2019 ACR/ARP Annual Meeting
Depression and Subsequent Risk for Incident Seronegative Rheumatoid Arthritis Among Women
Jeffrey Sparks¹, Susan Malspeis ¹, Jill Hahn ², Andrea Roberts ², Laura Kubzansky ² and Karen Costenbader ¹, ¹Brigham and Women's Hospital, Boston, MA, ²Harvard School of Public Health, Boston, MA
Background/Purpose: Depression is associated with elevated systemic inflammation and risk of several chronic diseases including lupus, psoriasis, and inflammatory bowel disease. However, the association between…
Abstract Number: 2823 • 2019 ACR/ARP Annual Meeting
Progression to Inflammatory Arthritis After Screening Autoantibody Positive in a Non-Clinical Setting
Jill Norris¹, Elizabeth Bemis ², Marie Feser ³, M. Kristen Demoruelle ⁴, Jennifer Seifert ⁵, Michael Weisman ⁶, Jane Buckner ⁷, Peter Gregersen ⁸, Ted Mikuls ⁹, James O'Dell ⁹, Richard M. Keating ¹⁰, Kevin Deane ³ and V. Michael Holers ⁵, ¹Colorado School of Public Health, Aurora, ²University of Colorado Denver, School of Public Health, Aurora, CO USA, Aurora, ³University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora, CO, ⁴University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora, ⁵University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Denver, ⁶David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁷Benaroya Research Institute, Seattle, WA, ⁸Feinstein Institutes for Medical Research, Manhasset, NY, ⁹VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha, NE, ¹⁰Scrippshealth, La Jolla
Background/Purpose: Rheumatoid arthritis (RA)-related autoantibodies are typically elevated prior to the onset of seropositive RA. Screening for autoantibody (aAb) positive individuals is a means to…
Abstract Number: L15 • 2018 ACR/ARHP Annual Meeting
The Diagnostic Accuracy of PET/CT Scan of the Head, Neck and Thorax Compared with Temporal Artery Biopsy in Patients Newly Suspected of Having GCA
Anthony Sammel¹, Edward Hsiao², Geoffrey Schembri³, Katherine Nguyen⁴, Janice Brewer⁴, Leslie Schrieber⁵, Beatrice Janssen⁴, Peter Youssef⁶, Clare Fraser⁷, Elizabeth Bailey⁸, Dale Bailey⁸, Paul Roach⁸ and Rodger Laurent⁴, ¹Rheumatology, Royal North Shore Hospital, St Leonards, Sydney, Australia, ²Royal North Shore Hospital, St Leonards, Australia, ³Nuclear Medicine, Royal North Shore Hospital, St Leonards, Australia, ⁴Royal North Shore Hospital, St Leonards, Sydney, Australia, ⁵Northern Clinical School, University of Sydney, Sydney, Australia, ⁶Royal Prince Alfred Hospital, Camperdown, Sydney, Australia, ⁷Save Sight Institute, Sydney, Australia, ⁸Royal North Shore Hospital, Sydney, Australia
Background/Purpose: The diagnostic accuracy of PET/CT against temporal artery biopsy (TAB) in patients suspected of having GCA has not been well studied. PET/CT has traditionally…
Abstract Number: L16 • 2018 ACR/ARHP Annual Meeting
Intra-Articular TPX-100 in Knee Osteoarthritis: Robust Functional Response at 6 and 12 Months Is Associated with Increased Tibiofemoral Cartilage Thickness
Dawn McGuire¹, Neil Segal², Samy Metyas³, Hans Richard Barthel⁴, Meghan Miller⁵, David Rosen⁵ and Yoshi Kumagai⁵, ¹Orthotrophix, Incorporated, Oakland, CA, ²Physical Medicine and Rehabilitation, University of Kansas Medical Center, Kansas City, KS, ³Medvin Clinical Research, Covina, CA, ⁴Barthel Clinic, Santa Barbara, CA, ⁵OrthoTrophix, Incorporated, Oakland, CA
Background/Purpose: TPX-100, a peptide derived from Matrix Extracellular Phosphoglycoprotein (MEPE), has been shown to induce articular cartilage regeneration after cartilage injury in animal models. A…
Abstract Number: L17 • 2018 ACR/ARHP Annual Meeting
Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Psa: Results from a 48-Week Phase 2b, Randomized, Double‑Blind, Placebo-Controlled, Dose-Ranging Study
Christopher T. Ritchlin¹, Arthur Kavanaugh², Joseph F. Merola³, Georg Schett⁴, Jose U. Scher⁵, Richard B. Warren⁶, Deepak Assudani⁷, Thomas Kumke⁸, Barbara Ink⁷ and Iain B. McInnes⁹, ¹University of Rochester Medical Centre, Rochester, NY, ²UC San Diego School of Medicine, La Jolla, CA, ³Brigham and Women's Hospital Harvard Medical School, Boston, MA, ⁴Friedrich Alexander University Erlangen-Nurnberg, Erlangen, Germany, ⁵Department of Medicine, NYU Langone Medical Center, New York, NY, ⁶The Dermatology Centre, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester, United Kingdom, ⁷UCB Pharma, Slough, United Kingdom, ⁸UCB Pharma, Monheim am Rhein, Germany, ⁹University of Glasgow, Glasgow, United Kingdom
Background/Purpose: IL-17F shares structural homology and overlapping biologic function with IL-17A. In vitro studies demonstrate that IL-17F has biologic effector function that can modulate inflammation.…
Abstract Number: L18 • 2018 ACR/ARHP Annual Meeting
A Randomized Controlled 24-Week Trial Evaluating the Safety and Efficacy of Blinded Tapering Versus Continuation of Long-Term Prednisone (5 mg/day) in Patients with Rheumatoid Arthritis Who Achieved Low Disease Activity or Remission on Tocilizumab
Gerd R. Burmester¹, Frank Buttgereit¹, Corrado Bernasconi², Jose Maria Alvaro-Gracia³, Nidia Castro², Maxime Dougados⁴, Cem Gabay⁵, Jacob van Laar⁶, J. Michael Nebesky², Attila Pethö-Schramm², Carlo Salvarani⁷, Marc Y. Donath⁸ and Markus R. John², ¹Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany, ²F. Hoffmann-La Roche, Basel, Switzerland, ³Hospital Universitario de La Princesa IIS-IP, Madrid, Spain, ⁴Université Paris-Descartes, Paris, France, ⁵University Hospitals of Geneva, Geneva, Switzerland, ⁶University Medical Centre Utrecht, Utrecht, Netherlands, ⁷Università de Modena e Reggio Emilia, Modena, Italy, ⁸University Hospital Basel, Basel, Switzerland
Background/Purpose: Guidelines recommend low-dose, short-duration glucocorticoid (GC) treatment for RA,1,2 but long-term use, especially at prednisone-equivalent doses >5 mg/d, should be avoided.2 Many patients (pts)…
Abstract Number: L19 • 2018 ACR/ARHP Annual Meeting
Transcutaneous Electrical Nerve Stimulation (TENS) Reduces Pain and Fatigue and Improves Disease Impact in Women with Fibromyalgia: A Randomized Controlled Trial
Leslie Crofford¹, Dana Daily², Carol Vance³, Ruth Chimenti², Ericka Merriwether⁴, Miriam Bridget Zimmerman⁵, Jonathan Williams⁶, Meena Golchha⁶, Li Alemo Munters⁷, Katharine Geasland³, Barbara Rakel⁸ and Kathleen Sluka², ¹Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN, ²Physical Therapy, University of Iowa, Iowa City, IA, ³University of Iowa, Iowa City, IA, ⁴Physical Therapy, New York University, New York, NY, ⁵Public Health, University of Iowa, Iowa City, IA, ⁶Vanderbilt University Medical Center, Nashville, TN, ⁷Karolinska Institutet, Stockholm, Sweden, ⁸Nursing, University of Iowa, Iowa City, IA
Background/Purpose: Fibromyalgia (FM) is a chronic pain condition associated with pain and fatigue, especially during physical activity. Treatments designed to modulate central pain pathways to…
Abstract Number: L20 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of Subcutaneous Tanezumab for the Treatment of Osteoarthritis of the Hip or Knee
Thomas J. Schnitzer¹, Richard Easton², Shirley Pang³, Dennis Levinson⁴, Glenn Pixton⁵, Lars Viktrup⁶, Isabelle Davignon⁷, Mark T. Brown⁷, Kenneth M. Verburg⁷ and Christine R. West⁷, ¹Northwestern University, Chicago, IL, ²Michigan Orthopaedic & Spine Surgeons, Rochester Hills, MI, ³St. Jude Medical Center, Fullerton, CA, ⁴Chicago Clinical Research Institute, Chicago, IL, ⁵Pfizer, Inc., Morrisville, NC, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Pfizer, Inc., Groton, CT
Background/Purpose: Tanezumab is a humanized mAb that blocks nerve growth factor (NGF) and is in clinical development for chronic pain treatment. Tanezumab administered intravenously has…
Abstract Number: L01 • 2018 ACR/ARHP Annual Meeting
New Cardiovascular Events in Patients with Gout Treated with Xanthine-Oxidase Inhibitors: An Inception Cohort Analysis
Neus Quilis¹, Laura Ranieri², Jose Sanchez-Paya² and Mariano Andrés², ¹Hospital Universitario del Vinalopó, Elche, Spain, ²Hospital General Universitario de Alicante-ISABIAL, Alicante, Spain
Background/Purpose: The recent CARES trial findings have contributed to the controversy around the development of cardiovascular (CV) events in gouty patients using febuxostat (FBX). In…
Abstract Number: L02 • 2018 ACR/ARHP Annual Meeting
Study of Tofacitinib in Refractory Dermatomyositis (STIR): An Open Label Pilot Study in Refractory Dermatomyositis
Julie J. Paik¹, Jemima Albayda², Eleni Tiniakou³, Andrew Koenig⁴ and Lisa Christopher-Stine⁵, ¹Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Pfizer Inc, Collegeville, PA, ⁵Medicine, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Dermatomyositis (DM) is an idiopathic inflammatory myopathy that primarily affects the muscle and skin. In refractory disease, it is common to fail 2 or…
Abstract Number: L03 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety from a Phase 2b Trial of SM04690, a Novel, Intra-Articular, Wnt Pathway Inhibitor for the Treatment of Osteoarthritis of the Knee
Yusuf Yazici¹, Timothy E. McAlindon², Allan Gibofsky³, Nancy Lane⁴, Christian Lattermann⁵, Nebojsa Skrepnik⁶, Christopher Swearingen¹, Anita DiFrancesco¹, Jeymi Tambiah¹ and Marc Hochberg⁷, ¹Samumed, LLC, San Diego, CA, ²Division of Rheumatology, Tufts Medical Center, Boston, MA, ³Rheumatology, Weill Cornell Medicine, and Hospital for Special Surgery, New York, NY, ⁴Center for Musculoskeletal Health, University of California, Davis School of Medicine, Sacramento, CA, ⁵Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁶Tucson Orthopaedic Institute, Tucson, AZ, ⁷University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: A previous Phase 2a study of SM04690, a small molecule, intra-articular (IA), Wnt pathway inhibitor, demonstrated positive effects on knee OA pain, physical function,…
Abstract Number: L04 • 2018 ACR/ARHP Annual Meeting
Pediatric Open-Label Clinical Study of Rituximab for the Treatment of Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)
Paul Brogan¹, Gavin Cleary², Aimee O. Hersh³, Ozgur Kasapcopur⁴, Satyapal Rangaraj⁵, Rae S.M. Yeung⁶, Andrew Zeft⁷, Simone Melega⁸, Paul Brunetta⁹, Jennifer Cooper¹⁰, Pooneh Pordeli¹¹ and Patricia B. Lehane¹², ¹Infection Inflammation and Rheumatology, UCL GOL Institute of Child Health, and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ²Alder Hey Children's Hospital, Liverpool, United Kingdom, ³Pediatrics/Rheumatology, University of Utah, Salt Lake City, UT, ⁴Cerrahpasa Medical School, Istanbul University, Istanbul, Turkey, ⁵Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom, ⁶Paediatrics, Immunology and Medical Science, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ⁷Center for Pediatric Rheumatology & Immunology, The Cleveland Clinic Foundation, Cleveland, OH, ⁸F. Hoffmann-La Roche, Basel, Switzerland, ⁹Genentech, Inc., South San Francisco, CA, ¹⁰Pediatric Rheumatology, Univ. of California San Francisco, San Francisco, CA, ¹¹Hoffmann-La Roche Ltd., Mississauga, ON, Canada, ¹²Roche Products Ltd., Welwyn Garden City, United Kingdom
Background/Purpose: PePRS is a Phase IIa international, multicenter, open-label single arm study of rituximab in pediatric patients with newly diagnosed or relapsing GPA or MPA.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].